Peptide · Fact sheet
Rusfertide
Also known as PTG-300 · Mimrylo
FDA approved Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera. Approval is specific to that product and population; it does not establish general iron-management or wellness uses.
What is Rusfertide?
Rusfertide is a manufactured peptide that mimics hepcidin, the hormone that regulates iron availability.
By restricting iron available for red-blood-cell production, it is designed to help control hematocrit and reduce the need for phlebotomy in polycythemia vera.
Benefits & claims
It applies peptide design to iron regulation and red-blood-cell production in a defined blood disorder.
An approval decision is distinct from evidence about long-term thrombosis, disease progression or survival.
What the evidence supports
- The Phase 2 REVIVE trial found better composite response during randomized withdrawal with rusfertide than placebo.
- FDA reports that the pivotal trial found fewer patients meeting phlebotomy criteria with Mimrylo than placebo.
Research areas
- Polycythemia vera
- Hematocrit control
- Reducing phlebotomy burden
- Symptoms related to polycythemia vera
- Other populations and outcomes outside the approved product scope
Dosage & frequency
Product-specific label informationMimrylo has a hematocrit-guided adult regimen for polycythemia vera. The starting amount is not a universal maintenance dose.
Mimrylo
Adults with erythrocytosis associated with polycythemia vera
- Amount
- 19 mg starting amount
- Frequency
- Once weekly initially
- Route studied or labeled
- Subcutaneous
Further amounts and high-dose divided schedules depend on hematocrit and the label.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- The label specifies special divided schedules for higher total weekly amounts.
Interactions & precautions
- The label has in-vitro interaction assessments; these cannot establish compatibility with every medicine or supplement used in polycythemia vera.
What is still unresolved
- Dose adjustment depends on hematologic response and specialist monitoring.
Side effects & risks
- The FDA label warns of new or worsening thrombocytosis (a high platelet count), injection-site reactions, and possible fetal harm based on animal studies.
- Injection-site reactions and anemia were the most common adverse reactions in the approval study. Blood-count changes are relevant to this iron-regulating treatment.
- The label does not establish pediatric safety and effectiveness, and advises against breastfeeding during treatment because of possible serious effects on the child.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceFDA reports that the 293-participant randomized Phase 3 VERIFY trial supported approval. The measured phlebotomy outcome should not be substituted for evidence of longer survival or prevention of thrombosis.
Studies
Official record for the 293-participant pivotal trial, including endpoints and public results status.
Peer-reviewed Phase 2 evidence for hematocrit control and phlebotomy reduction.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
For this question, the FDA decision below is the main source. It explains the evidence behind the approval and its limits.
What these results can and cannot tell us
Is the rusfertide FDA application still pending?
FDA approved Mimrylo; earlier pending-review language is superseded.
Limit: An approval announcement does not establish every long-term outcome or constitute a complete safety review.
Check the sources: FDA Mimrylo approval (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Mimrylo: Polycythemia vera
Subcutaneous injection · Adults with polycythemia vera
approved — Approval does not establish other iron-related or wellness uses. The announcement is not a complete safety label.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18 · Decision: 2026-08-28
Compare research questions · Submit a source-based correction
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Fewer blood removals and easier daily life, with brief local discomfort
A person with polycythemia vera described a return to work and family activities after joining a rusfertide trial, with a brief sensation at the injection site.
Reported use in this account
- Product
- Rusfertide clinical-trial treatment
- Amount
- Not specified clearly
- Frequency
- Once weekly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
This selected hospital-published interview concerns one trial participant. Outcomes and treatment exposure were not independently checked, and it does not predict an individual response.
Read the patient interviewFatigue persisted during a rusfertide trial
Another person with polycythemia vera described continuing severe fatigue despite trying a rusfertide trial after several other treatments.
Amount, frequency, route and duration could not be confirmed for this account.
The comment does not state trial allocation, rusfertide amount, duration or clinical measurements. The author described prior hydroxyurea and ruxolitinib, later ropeginterferon and a stimulant for persistent fatigue; underlying illness and changing treatment complicate interpretation.
Read the original accountFocus: reported experiences
Fatigue persisted during a rusfertide trial
Another person with polycythemia vera described continuing severe fatigue despite trying a rusfertide trial after several other treatments.
Amount, frequency, route and duration could not be confirmed for this account.
The comment does not state trial allocation, rusfertide amount, duration or clinical measurements. The author described prior hydroxyurea and ruxolitinib, later ropeginterferon and a stimulant for persistent fatigue; underlying illness and changing treatment complicate interpretation.
Read the original accountPain: reported experiences
Fewer blood removals and easier daily life, with brief local discomfort
A person with polycythemia vera described a return to work and family activities after joining a rusfertide trial, with a brief sensation at the injection site.
Reported use in this account
- Product
- Rusfertide clinical-trial treatment
- Amount
- Not specified clearly
- Frequency
- Once weekly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
This selected hospital-published interview concerns one trial participant. Outcomes and treatment exposure were not independently checked, and it does not predict an individual response.
Read the patient interviewLess itching and fewer phlebotomies, with injection-site soreness
A separate trial participant reported fewer therapeutic blood removals, improved iron measurements and less itching, but temporary local soreness and continuing treatment for high platelets.
Reported use in this account
- Product
- Rusfertide clinical-trial treatment
- Amount
- Not specified clearly
- Frequency
- Once weekly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Other exposures described: Hydroxyurea
The reported laboratory changes are not supported by accessible medical records. Hydroxyurea was also used; the account is specific to polycythemia vera and does not establish benefit for other causes of high blood counts.
Read the original accountSkin: reported experiences
Less itching and fewer phlebotomies, with injection-site soreness
A separate trial participant reported fewer therapeutic blood removals, improved iron measurements and less itching, but temporary local soreness and continuing treatment for high platelets.
Reported use in this account
- Product
- Rusfertide clinical-trial treatment
- Amount
- Not specified clearly
- Frequency
- Once weekly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Other exposures described: Hydroxyurea
The reported laboratory changes are not supported by accessible medical records. Hydroxyurea was also used; the account is specific to polycythemia vera and does not establish benefit for other causes of high blood counts.
Read the original accountNo clear change: reported experiences
Fatigue persisted during a rusfertide trial
Another person with polycythemia vera described continuing severe fatigue despite trying a rusfertide trial after several other treatments.
Amount, frequency, route and duration could not be confirmed for this account.
The comment does not state trial allocation, rusfertide amount, duration or clinical measurements. The author described prior hydroxyurea and ruxolitinib, later ropeginterferon and a stimulant for persistent fatigue; underlying illness and changing treatment complicate interpretation.
Read the original accountApproval status
FDA approved Mimrylo for erythrocytosis in adults with polycythemia vera. Earlier application-acceptance and priority-review records are historical milestones, superseded by the approval decision.
Approved uses
- Treatment of erythrocytosis in adults with polycythemia vera under the Mimrylo approval
Mimrylo approved for a defined adult blood disorder
FDA approved Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera. Earlier priority-review records are historical and no longer describe a pending decision.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- The full long-term safety profile with broader clinical exposure
- Long-term effects on thrombosis, disease progression, symptoms, and survival
- Uncommon harms with broader exposure
- How it compares with established polycythemia vera strategies on patient-centered outcomes
Summary
Rusfertide has a product-specific FDA approval for adults with polycythemia vera. Evidence for reduced phlebotomy requirements does not answer every question about long-term patient outcomes.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: Mimrylo prescribing information
August 2026 label: indication, platelet-count warning, injection-site reactions, anemia and reproductive risks.
- fdaFDA: Mimrylo approval for polycythemia vera
Product-specific approval decision and pivotal-trial summary.
- fdaFDA novel drug approvals: Mimrylo
FDA identifies the approved use as erythrocytosis in adults with polycythemia vera.
- clinical trialsClinicalTrials.gov: VERIFY Phase 3 trial
Official record for the 293-participant pivotal trial, including endpoints and public results status.
- pubmedREVIVE randomized-withdrawal trial
Peer-reviewed Phase 2 evidence for hematocrit control and phlebotomy reduction.
- company releaseTakeda: FDA accepts rusfertide application
Company-reported application acceptance and priority-review milestone; not an FDA approval decision.
- educationalSEC filing: rusfertide regulatory status
Public company filing confirming submission and pending review of the application.